Host: Javed Butler, MD, MBA, MPH 


  Guest: Mikhail Kosiborod, MD 



  
    With the prevalence of heart failure continuing to rise worldwide, recent trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors may improve impairments and decrease the risk of hospitalizations. So based on these recent findings, what exactly is their role in the management of patients with heart failure? Find out with Dr. Javed Butler as he speaks with Dr. Mikhail Kosiborod, Professor of Medicine at the University of Missouri-Kansas City and Vice-President of Research at Saint Luke's Health System.

Reviewing the Role of SGLT2 Inhibitors in Heart Failure

Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more.
So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Host: Javed Butler, MD, MBA, MPH 


  Guest: Michael J. LaMonte, PhD, MPH 



  
    The American Heart Association recommends physical activity to help lower the risk of heart failure, but how much exercise is needed, especially for older women, to lower that risk? According to a recent study, even just low-intensity exercise for 30 minutes is associated with a 25 percent lower risk of overall heart failure. Dive further into the findings with Dr. Javed Bulter and Dr. Michael LaMonte, a Research Professor of Epidemiology and Environmental Health at the University of Buffalo.

Active Aging: Preventing Heart Failure in Older Women with Exercise

Host: Javed Butler, MD, MBA, MPH 


  Guest: Jeffrey Wilson, MD 



  
    There’s a decent amount of evidence showing allergic immune responses could have connections with heart disease. But with the knowledge gaps that exist, a need for bigger cohorts is necessary to get more information and data. So to explore the link between allergic reactions from food and heart disease, Dr. Javed Butler is joined by Dr. Jeffrey Wilson, Allergist and Immunologist in the Department of Medicine’s Division of Asthma, Allergy, and Immunology at the University of Virginia. 

Allergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link

Host: Javed Butler, MD, MBA, MPH 


  Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S. 



  
    For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.

AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD

Guest: Michael Farbaniec, MD 


  Guest: Emma Hegwood, DO 


  Guest: Britt Heller, MSN, RN 



  
    Explore the acquisition pathways and learn key strategies for implementing LEQVIO® (inclisiran) into your practice with Dr Michael Farbaniec, Lipid Clinic Director in Pennsylvania, Dr Emma Hegwood, a cardiology fellow with Dr Farbaniec in the Clinical World of Cardiology and also a LEQVIO patient, and Care Coordinator and Registered Nurse Brittany Heller. Dr Farbaniec, Dr Hegwood, and Ms Heller have all been compensated for their time.

Implementing LDL-C—Lowering Therapy: Conversations with the Care Team

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA 


  Guest: Dave L. Dixon, PharmD, FACC,  FCCP, FNLA, BCPS, BCACP, CDE, CLS 



  
    What would the cost-effectiveness look like if the uptake of a pharmacist-prescribing model for hypertension were to be put into practice? A new study shows that a pharmacist-prescribing method could have significant economic impact on the U.S. healthcare system. Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Dave Dixon, Nancy L. and Ronald H. McFarlane Professor of Pharmacy at Virginia Commonwealth University School of Pharmacy, to discuss the findings from the study, titled “Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States,” which was published in JAMA Network. 

Reviewing the Role of SGLT2 Inhibitors in Heart Failure

Download our free app to listen on your phone